Research Pipeline


Molecule Indication MoA/Class
Pre-Clinical Phase 1 Phase 2 a Phase 2 b Phase 3 Approval
GBR 830 Atopic dermatitis OX40 Antagonist (mAb)
+
Immunology
GBR 830 - Systemic Lupus Erythematosus (SLE) - Ulcerative Colitis (UC) OX40 Antagonist
+
Immunology
GRC 39815 COPD ROR γ t inhibitor
+
Immunology
GBR 1302 HER2 positive cancers such as Breast Cancer and Gastric Cancer HER2xCD3 (bispecific mAb)
+
Oncology
GBR 1342 Multiple myeloma, Solid Tumors CD38xCD3 (bispecific mAb)
+
Oncology
GBR 1372 Colorectal Cancer EGFRxCD3 (bispecific mAb)
+
Oncology
TBD TBD MAP4K1 Inhibitor
+
Oncology
GRC 27864 Osteoarthritic Pain mPGES-1 Inhibitor
+
Pain
GRC 17536 Neuropathic Pain TRPA1 Antagonist
+
Pain

Non-core assets include GBR 900 and GBR 500. These 2 molecules and GRC 27864 are candidates for out-licensing

Ryaltris™ has been conditionally accepted as the brand name for GSP 301 Nasal Spray by the U.S. Food & Drug Administration (FDA)

Pipeline updated as of January 2019.

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future
Know More